Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | FGFR1 A354V |
| Therapy | Pemigatinib |
| Indication/Tumor Type | esophageal carcinoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FGFR1 A354V | esophageal carcinoma | predicted - sensitive | Pemigatinib | Case Reports/Case Series | Actionable | In a Phase I trial, Pemazyre (pemigatinib) treatment resulted in an objective response rate of 16.7% (2/12, both partial responses) and a disease control rate of 41.7% (5/12) in patients with advanced solid tumors harboring FGFR1/2/3 alterations including amplification, mutation, or fusion, including a partial response in a patient with esophageal carcinoma harboring FGFR1 A354V (PMID: 37889382; NCT04258527). | 37889382 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (37889382) | Pharmacokinetics, pharmacodynamics and efficacy of pemigatinib (a selective inhibitor of fibroblast growth factor receptor 1-3) monotherapy in Chinese patients with advanced solid tumors: a phase i clinical trial. | Full reference... |